PE20230159A1 - Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos - Google Patents

Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos

Info

Publication number
PE20230159A1
PE20230159A1 PE2022001098A PE2022001098A PE20230159A1 PE 20230159 A1 PE20230159 A1 PE 20230159A1 PE 2022001098 A PE2022001098 A PE 2022001098A PE 2022001098 A PE2022001098 A PE 2022001098A PE 20230159 A1 PE20230159 A1 PE 20230159A1
Authority
PE
Peru
Prior art keywords
alkyl
oxoisoindolin
piperidin
methoxy
dione
Prior art date
Application number
PE2022001098A
Other languages
English (en)
Inventor
Simone Bonazzi
Artiom Cernijenko
Jennifer Stroka Cobb
Natalie Dales
John Ryan Kerrigan
Philip Lam
Hasnain Ahmed Malik
Gary O'brien
Andrew W Patterson
Noel Marie-France Thomsen
Pamela Ting
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20230159A1 publication Critical patent/PE20230159A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona de formula (I'); en donde Y es O, CH2, CF2, y CHF; z es de 0 a 2; RX1 y RX2 es cada uno, independientemente, H y alquilo C1-C6; RY1 y RY2 es cada uno, independientemente, H y alquilo C1-C6; RZ1 y RZ2 son ambos hidrogeno; R1 es H y alquilo C1-C6; R2 es H, -C(=O)-R3 , cicloalquilo C3-C8, haloalquilo C1-C6 y alquilo C1-C10. Un compuesto seleccionado es 3-(5-(((R)-1-((1-ciclohexil-1H-pirazol-4-il)metil) piperidin-2-il)metoxi)-1-oxoisoindolin-2- il)piperidin-2,6-diona. Tambien refiere a una composicion farmaceutica que los comprende. Dichos compuestos son efectivos para reducir los niveles de expresion de la proteina Motivos de Dedos de Zinc Ampliamente Interespaciados (WIZ) y/o para inducir la expresion de la hemoglobina fetal (HbF), siendo util en el tratamiento de trastornos sanguineos hereditarios (hemoglobinopatias, beta-hemoglobinopatias), tales como la enfermedad de celulas falciformes y la betatalasemia.
PE2022001098A 2019-12-18 2020-12-16 Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos PE20230159A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950048P 2019-12-18 2019-12-18
PCT/IB2020/062070 WO2021124172A1 (en) 2019-12-18 2020-12-16 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PE20230159A1 true PE20230159A1 (es) 2023-02-01

Family

ID=73856242

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001098A PE20230159A1 (es) 2019-12-18 2020-12-16 Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos

Country Status (21)

Country Link
US (1) US11566022B2 (es)
EP (1) EP4076650B1 (es)
JP (1) JP2023506642A (es)
KR (1) KR20220114065A (es)
CN (1) CN114828959B (es)
AR (1) AR120773A1 (es)
AU (1) AU2020410514A1 (es)
BR (1) BR112022011796A2 (es)
CA (1) CA3164832A1 (es)
CO (1) CO2022008243A2 (es)
CR (1) CR20220278A (es)
DO (1) DOP2022000121A (es)
EC (1) ECSP22055267A (es)
ES (1) ES2980575T3 (es)
IL (1) IL293530A (es)
JO (1) JOP20220152A1 (es)
MX (1) MX2022007351A (es)
PE (1) PE20230159A1 (es)
TW (1) TW202130631A (es)
UY (1) UY38986A (es)
WO (1) WO2021124172A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021321416A1 (en) * 2020-08-07 2023-02-09 Cornell University Therapeutically useful cure-pro molecules for E3 ligase mediated degradation of proteins, and methods of making and using them
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
CN117062811A (zh) 2021-06-03 2023-11-14 诺华股份有限公司 3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其医疗用途
CN118556048A (zh) * 2022-12-27 2024-08-27 标新生物医药科技(上海)有限公司 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用
CN115959976A (zh) * 2022-12-30 2023-04-14 安徽诺全药业有限公司 一种甲氧基取代双环戊烷衍生物的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2433680A1 (en) 2000-12-28 2002-08-01 Gregory M Arndt Double-stranded rna-mediated gene suppression
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
ES2713482T3 (es) 2010-02-11 2019-05-22 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
JP2013543009A (ja) 2010-11-18 2013-11-28 デューテリア ファーマシューティカルズ， インコーポレイテッド ３−ジュウテロ−ポマリドマイド
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014018866A1 (en) 2012-07-27 2014-01-30 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
US20170038387A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
CA3018434A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
PL3660004T3 (pl) 2016-10-11 2023-10-02 Arvinas Operations, Inc. Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
KR102570992B1 (ko) 2016-11-01 2023-08-28 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
ES2967404T3 (es) 2016-12-01 2024-04-30 Arvinas Operations Inc Derivados de tetrahidronaftaleno y tetrahidroisoquinolina como degradadores del receptores de estrógenos
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
EP3559002A4 (en) 2016-12-23 2021-02-17 Arvinas Operations, Inc. CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
KR102582886B1 (ko) 2017-01-26 2023-09-26 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
EP3697436A1 (en) 2017-10-18 2020-08-26 Novartis AG Compositions and methods for selective protein degradation
WO2019079701A1 (en) 2017-10-20 2019-04-25 Dana-Farber Cancer Institute, Inc. HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
US11028088B2 (en) 2018-03-10 2021-06-08 Yale University Modulators of BTK proteolysis and methods of use
JP2021519337A (ja) * 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
EP3813829A4 (en) 2018-06-29 2021-12-08 Dana Farber Cancer Institute, Inc. LIGANDS FOR CEREBLON (CRB)
WO2020006265A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Bispecific degraders
EP3813834A4 (en) 2018-06-29 2022-03-09 Dana Farber Cancer Institute, Inc. NEW CRBN MODULATORS
CN113166100A (zh) 2018-06-29 2021-07-23 达纳-法伯癌症研究所有限公司 免疫调节性化合物
CN113490495B (zh) 2018-12-03 2024-09-27 达纳-法伯癌症研究公司 Helios的小分子降解剂及其使用方法

Also Published As

Publication number Publication date
CO2022008243A2 (es) 2022-07-08
IL293530A (en) 2022-08-01
US11566022B2 (en) 2023-01-31
UY38986A (es) 2021-07-30
MX2022007351A (es) 2022-07-19
KR20220114065A (ko) 2022-08-17
CN114828959B (zh) 2024-04-02
ES2980575T3 (es) 2024-10-02
BR112022011796A2 (pt) 2022-08-30
WO2021124172A1 (en) 2021-06-24
EP4076650A1 (en) 2022-10-26
JOP20220152A1 (ar) 2023-01-30
AU2020410514A1 (en) 2022-06-30
JP2023506642A (ja) 2023-02-17
CA3164832A1 (en) 2021-06-24
TW202130631A (zh) 2021-08-16
DOP2022000121A (es) 2022-08-15
AR120773A1 (es) 2022-03-16
US20220402904A1 (en) 2022-12-22
EP4076650B1 (en) 2024-02-28
CN114828959A (zh) 2022-07-29
CR20220278A (es) 2022-07-01
ECSP22055267A (es) 2022-08-31

Similar Documents

Publication Publication Date Title
PE20230159A1 (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
CY1121782T1 (el) Διαδικασια για ξηρανση της bibw2992, tων αλατων αυτης και στερεων φαρμακευτικων σκευασματων που περιλαμβανουν αυτο το δραστικο συστατικο
BR112022010599A2 (pt) Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
HRP20180199T1 (hr) Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1)
EA023500B1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
AR104714A1 (es) Compuestos depsipeptídicos como antihelmínticos
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR100463A1 (es) Composiciones pesticidas y métodos relacionados
BR112014015402A2 (pt) composição sólida de cuidado pessoal, produto de cuidado pessoal e método de tratar cabelo e/ou pele
RU2012158142A (ru) Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
AR065628A1 (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
BRPI0907122B8 (pt) compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
PE20151666A1 (es) Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
CL2023003561A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
CO2021017435A2 (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
JP2010520242A5 (es)
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
AR082137A1 (es) Derivados de bisaril(tio)morfolina como modulares s1p y composiciones farmaceuticas que los contienen